PBMs, Insurers Mobilize Against Trump's Drug Price Transparency Rule, Calling It Illegal

The Trump administration's push to force pharmacy benefit managers (PBMs) to disclose their secretive drug pricing data is meeting a coordinated legal and lobbying counteroffensive. The industry, which generates billions in annual profits as the gatekeepers of prescription drug spending, is warning that a proposed Department of Labor rule mandating wide-ranging disclosures to employers is unlawful. The public comment period, which closed last week, became a battleground for the entrenched financial interests at the heart of America's opaque drug pricing system.

A review of over 500 submitted comment letters reveals a stark divide. PBMs and the health insurers they often work with predictably mounted stiff resistance, framing the transparency mandate as an illegal overreach. In contrast, business interests like Mark Cuban's Cost Plus Drug Company enthusiastically backed the rule, arguing for greater accountability for the powerful middlemen. The pharmaceutical industry, meanwhile, offered a nuanced position: while cheering that regulatory scrutiny is focused on PBMs, drugmakers also sought to pull back on certain disclosure requirements that could affect them.

This clash signals a high-stakes regulatory fight that could reshape the flow of billions in drug spending. The proposed rule aims to empower employers—who sponsor most health plans—with the data to audit PBM contracts and understand true net costs. If implemented, it would apply significant pressure on the PBM business model, which has long thrived on complex rebates and hidden spreads between list and net prices. The industry's immediate legal warnings suggest a protracted battle ahead, with the outcome hinging on the administration's resolve to finalize the rule against intense opposition.